全文获取类型
收费全文 | 31782篇 |
免费 | 1608篇 |
国内免费 | 166篇 |
专业分类
耳鼻咽喉 | 375篇 |
儿科学 | 589篇 |
妇产科学 | 309篇 |
基础医学 | 4107篇 |
口腔科学 | 890篇 |
临床医学 | 2252篇 |
内科学 | 7791篇 |
皮肤病学 | 539篇 |
神经病学 | 2513篇 |
特种医学 | 1205篇 |
外科学 | 5041篇 |
综合类 | 194篇 |
一般理论 | 1篇 |
预防医学 | 1180篇 |
眼科学 | 476篇 |
药学 | 2756篇 |
中国医学 | 68篇 |
肿瘤学 | 3270篇 |
出版年
2022年 | 245篇 |
2021年 | 558篇 |
2020年 | 262篇 |
2019年 | 399篇 |
2018年 | 510篇 |
2017年 | 415篇 |
2016年 | 494篇 |
2015年 | 531篇 |
2014年 | 702篇 |
2013年 | 900篇 |
2012年 | 1311篇 |
2011年 | 1420篇 |
2010年 | 816篇 |
2009年 | 713篇 |
2008年 | 1230篇 |
2007年 | 1294篇 |
2006年 | 1323篇 |
2005年 | 1441篇 |
2004年 | 1338篇 |
2003年 | 1320篇 |
2002年 | 1376篇 |
2001年 | 1232篇 |
2000年 | 1365篇 |
1999年 | 1191篇 |
1998年 | 419篇 |
1997年 | 305篇 |
1996年 | 312篇 |
1995年 | 268篇 |
1994年 | 261篇 |
1993年 | 252篇 |
1992年 | 801篇 |
1991年 | 719篇 |
1990年 | 734篇 |
1989年 | 776篇 |
1988年 | 710篇 |
1987年 | 639篇 |
1986年 | 609篇 |
1985年 | 570篇 |
1984年 | 444篇 |
1983年 | 332篇 |
1982年 | 191篇 |
1980年 | 160篇 |
1979年 | 284篇 |
1978年 | 222篇 |
1977年 | 172篇 |
1974年 | 170篇 |
1973年 | 153篇 |
1971年 | 154篇 |
1969年 | 171篇 |
1968年 | 149篇 |
排序方式: 共有10000条查询结果,搜索用时 625 毫秒
991.
Ming-Dong Zhang Giuseppe Tortoriello Brian Hsueh Raju Tomer Li Ye Nicholas Mitsios Lotta Borgius Gunnar Grant Ole Kiehn Masahiko Watanabe Mathias Uhlén Jan Mulder Karl Deisseroth Tibor Harkany Tomas G. M. H?kfelt 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(12):E1149-E1158
Neuronal calcium (Ca2+)-binding proteins 1 and 2 (NECAB1/2) are members of the phylogenetically conserved EF-hand Ca2+-binding protein superfamily. To date, NECABs have been explored only to a limited extent and, so far, not at all at the spinal level. Here, we describe the distribution, phenotype, and nerve injury-induced regulation of NECAB1/NECAB2 in mouse dorsal root ganglia (DRGs) and spinal cord. In DRGs, NECAB1/2 are expressed in around 70% of mainly small- and medium-sized neurons. Many colocalize with calcitonin gene-related peptide and isolectin B4, and thus represent nociceptors. NECAB1/2 neurons are much more abundant in DRGs than the Ca2+-binding proteins (parvalbumin, calbindin, calretinin, and secretagogin) studied to date. In the spinal cord, the NECAB1/2 distribution is mainly complementary. NECAB1 labels interneurons and a plexus of processes in superficial layers of the dorsal horn, commissural neurons in the intermediate area, and motor neurons in the ventral horn. Using CLARITY, a novel, bilaterally connected neuronal system with dendrites that embrace the dorsal columns like palisades is observed. NECAB2 is present in cell bodies and presynaptic boutons across the spinal cord. In the dorsal horn, most NECAB1/2 neurons are glutamatergic. Both NECAB1/2 are transported into dorsal roots and peripheral nerves. Peripheral nerve injury reduces NECAB2, but not NECAB1, expression in DRG neurons. Our study identifies NECAB1/2 as abundant Ca2+-binding proteins in pain-related DRG neurons and a variety of spinal systems, providing molecular markers for known and unknown neuron populations of mechanosensory and pain circuits in the spinal cord.Calcium (Ca2+) plays a crucial role in many and diverse cellular processes, including neurotransmission (1). Glutamate and neuropeptides are neurotransmitters released from the central terminals of dorsal root ganglion (DRG) neurons in the spinal dorsal horn, where signals for different sensory modalities, including pain, are conveyed to higher centers (2–12). Neurotransmitter release is tightly regulated by Ca2+-dependent SNARE proteins whose activity is regulated by Ca2+-binding proteins (CaBPs) (1, 7, 13).Parvalbumin (PV), calbindin D-28K (CB), calretinin (CR), and secretagogin (Scgn) are extensively studied EF-hand CaBPs, and they have also emerged as valuable anatomical markers for morphologically and functionally distinct neuronal subpopulations (14–17). The expression of CaBPs in DRG neurons has been thoroughly studied (18). Moreover, neuronal Ca2+ sensor 1 and downstream regulatory element-antagonist modulator (DREAM) are also EF-hand Ca2+-binding proteins in DRGs and the spinal cord (19, 20). Despite these advances, a CaBP has so far not been characterized in the majority of small- and medium-sized DRG neurons, many of which represent nociceptors.The subfamily of neuronal Ca2+-binding proteins (NECABs) consists of three members (NECAB1–NECAB3), probably as a result of gene duplication (21). NECABs are also EF-hand proteins, with one pair of EF-hand motifs in the N terminus and a putative antibiotic biosynthesis monooxygenase domain in the C terminus, which are linked by a NECAB homogeneous region (22). NECAB1/2 are restricted to the nervous system, whereas NECAB3 is also expressed in the heart and skeletal muscle (21).NECAB1 was first identified as the target protein of synaptotagmin I C2A-domain by affinity chromatography, with its expression restricted to layer 4 cortical pyramidal neurons, inhibitory interneurons, and hippocampal CA2 pyramidal cells in mouse brain (21, 23). The gene of the second member was cloned from mouse and initially named Necab. It encodes a 389-aa (NECAB2) (24). NECAB2 was identified as a downstream target of Pax6 in mouse retina, which is involved in retinal development (24, 25), as well as being a binding partner for the adenosine A2A receptor (22). Furthermore, an interaction between NECAB2 and metabotropic glutamate receptor 5 (mGluR5) was demonstrated in rat hippocampal pyramidal cells, possibly regulating mGluR5’s coupling to its signaling machinery (26). Finally, NECAB3, also known as XB51, was isolated as an interacting target for the neuron-specific X11-like protein and is possibly involved in the pathogenesis of Alzheimer’s disease (27, 28).Very recently, NECAB1/2 were shown to have complementary expression patterns in mouse hippocampus at the mRNA and protein levels, whereas NECAB3 is broadly distributed in the hippocampus (29). NECAB1-expressing cells were seen throughout the cell-sparse layers of Ammon’s horn and the hilus of the dentate gyrus. In contrast, NECAB2 is enriched in pyramidal cells of the CA2 region. A minority of NECAB1+ neurons were GABAergic yet did not coexpress PV, CB, or CR (29).Here, we investigated the expression of NECAB1/2 in mouse DRGs and spinal cord using quantitative PCR (qPCR), immunohistochemistry (also combined with CLARITY) (30), and Western blotting. We compared the distribution of NECABs with that of the four CaBPs restricted to neurons, PV, CB, CR, or Scgn. NECAB+ neurons in the spinal dorsal horn were phenotyped using transgenic mice harboring genetic markers for excitatory [vesicular glutamate transporter 2 (VGLUT2)] (31) or inhibitory [glutamate decarboxylase 67 (GAD67)] (32) cell identities. Finally, the effect of peripheral nerve injury was analyzed. 相似文献
992.
993.
994.
995.
996.
Ohta Shin Tanaka Akihiko Jinno Megumi Hirai Kuniaki Miyata Yoshito Yamaguchi Munehiro Homma Tetsuya Muramoto Mayumi Watanabe Yoshio Suzuki Shintaro Yokoe Takuya Sagara Hironori 《Sleep & breathing》2020,24(2):523-532
Sleep and Breathing - Obesity increases the severity of asthma, and patients with severe asthma are often complicated with obstructive sleep apnea syndrome (OSAS), a concomitant disease of obesity.... 相似文献
997.
Nobuhiro Yoshijima Ryo Yanagisawa Hiromu Hase Makoto Tanaka Hikaru Tsuruta Hideyuki Shimizu Keiichi Fukuda Toru Naganuma Kazuki Mizutani Motoharu Araki Norio Tada Futoshi Yamanaka Shinichi Shirai Minoru Tabata Hiroshi Ueno Kensuke Takagi Akihiro Higashimori Yusuke Watanabe Masanori Yamamoto Kentaro Hayashida 《Catheterization and cardiovascular interventions》2020,95(1):35-44
998.
Hiroshi Kimura Kenichi Tanaka Makoto Kanno Kimio Watanabe Yoshimitsu Hayashi Koichi Asahi Hodaka Suzuki Keiji Sato Michiaki Sakaue Hiroyuki Terawaki Masaaki Nakayama Toshio Miyata Tsuyoshi Watanabe 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2014,18(5):461-467
Tissue accumulation of advanced glycation end products (AGE) is thought to contribute to the progression of cardiovascular disease (CVD). Skin autofluorescence, a non‐invasive measure of AGE accumulation using autofluorescence of the skin under ultraviolet light, has been reported to be an independent predictor of mortality associated with CVD in Caucasian patients on chronic hemodialysis. The aim of this study was to assess the predictive value of skin autofluorescence on all‐cause and cardiovascular mortality in non‐Caucasian (Japanese) patients on chronic hemodialysis. Baseline skin autofluorescence was measured with an autofluorescence reader in 128 non‐Caucasian (Japanese) patients on chronic hemodialysis. All‐cause and cardiovascular mortality was monitored prospectively during a period of 6 years. During the follow‐up period, 42 of the 128 patients died; 19 of those patients died of CVD. Skin autofluorescence did not have a significant effect on all‐cause mortality. However, age, carotid artery intima‐media thickness (IMT), serum albumin, high‐sensitivity C‐reactive protein (hsCRP), skin autofluorescence and pre‐existing CVD were significantly correlated with cardiovascular mortality. Multivariate Cox regression analysis showed skin autofluorescence (adjusted hazard ratio [HR] 3.97; 95% confidence interval [CI]1.67–9.43), serum albumin (adjusted HR 0.05; 95% CI 0.01–0.32), and hsCRP (adjusted HR 1.55; 95% CI 1.18–2.05) to be independent predictors of cardiovascular mortality. The present study suggests that skin autofluorescence is an independent predictor of cardiovascular mortality in non‐Caucasian (Japanese) patients on chronic hemodialysis. 相似文献
999.
Tadao Akizawa Akira Saito Fumitake Gejyo Masashi Suzuki Yoshiki Nishizawa Yasuhiko Tomino Yoshiharu Tsubakihara Takashi Akiba Hideki Hirakata Yuzo Watanabe Hideki Kawanishi Masami Bessho Yukio Udagawa Kotonari Aoki Yukari Uemura Yasuo Ohashi Co‐JET Study Group 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2014,18(2):140-148
The effect of recombinant human erythropoietin (rHuEPO) treatment on the progression of chronic kidney disease (CKD) has not been fully evaluated in Japan. We therefore retrospectively evaluated this in a sub‐cohort of a prospective multicenter study to investigate optimal hemoglobin (Hb) level of CKD patients on hemodialysis (HD) treated with rHuEPO; Japan Erythropoietin Treatment Study for Target Hb and Survival (JET study). Effect of rHuEPO treatment during predialysis period to delay initiation of HD was retrospectively assessed in 2434 patients from the JET study comparing groups with and without rHuEPO treatment. The assessment was done by Cox proportional hazards regression analysis and inverse probability‐weighted (IPW) analysis to adjust for time‐dependent confounders. The weights used in the IPW analysis were calculated using a logistic model that included baseline confounders and time‐dependent variables. During the predialysis period, 71.7% (1746 patients) were treated with rHuEPO (mean Hb level of 8.7 g/dL at initiation of rHuEPO treatment). Covariates significantly associated with initiation of rHuEPO treatment were Hb level, serum creatinine level, age, diabetes, cardiac insufficiency, and hypertension. The adjusted hazard ratio for time until HD initiation under rHuEPO treatment was 0.272 (95% CI, 0.223–0.331; P < 0.001) in the Cox analysis and 0.63 (95% CI, 0.53–0.76; P < 0.0001) in the IPW analysis. This retrospective study suggests that rHuEPO treatment during the predialysis period has preventive effects on the progression of CKD although further prospective investigation on the efficacy is needed. 相似文献
1000.
Osamu Maeda Takafumi Ando Kazuhiro Ishiguro Osamu Watanabe Ryoji Miyahara Masanao Nakamura Kohei Funasaka Kazuhiro Furukawa Yuichi Ando Katsuhiko Kato Hidemi Goto 《Clinical journal of gastroenterology》2014,7(5):387-391
A 75-year-old woman was diagnosed with esophageal cancer with difficulty in swallowing. She had a past history of rheumatoid arthritis, scleroderma, interstitial pneumonia, angina pectoris (with coronary artery bypass surgery) and arrhythmia (with pacemaker implantation). She refused surgery, and chemotherapy and radiotherapy were not performed because of the high risk accompanied with multiple comorbidities. She received proton therapy at another hospital and the primary lesion shrank. Bone metastasis in the thoracic vertebrae was diagnosed 10 months after diagnosis of esophageal cancer. Non-steroidal anti-inflammatory drugs and zoledronic acid were administered for back pain. Oxycodone was also administered but discontinued due to nausea. After strontium-89 (89Sr) chloride administration, her back pain was relieved. 89Sr was administered five times every 3 months, and the pain did not worsen until her death due to pneumonia 2 years after diagnosis of esophageal cancer. 89Sr was effective for pain from bone metastasis of esophageal cancer, and its repeated administration was safe. 相似文献